Funding, M&A, exec moves and hiring — matched to your market, with the people to call.See plans →
Expedition Therapeutics raised $115M in Series B funding, led by General Atlantic. The firm will use the capital to advance its lead DPP1 inhibitor EXPD-101 through Phase 2 clinical development.
PRIVATEAug 05, 2026•4 days ago
Amount Raised
$115 Million
Round Type
Series B
San FranciscoBiotechnologyHealth CareresearchInvestors
Venrock Healthcare Capital PartnersBvf PartnersSanofi VenturesLogos CapitalBalyasny Asset ManagementAdage Capital ManagementDawn BiopharmaForbionNovo HoldingsSofinnova InvestmentsVivo CapitalRa CapitalGeneral Atlantic
Description
Expedition Therapeutics, a San Francisco, CA-based clinical-stage biotechnology platform, raised $115M in Series B financing. The round was led by General Atlantic with participation from several investors. The funds will support the advancement of their lead DPP1 inhibitor EXPD-101 and expand their therapy pipeline. Their innovative platform targets neutrophil-driven diseases.
Related People
Suggested for you
2 contactsVerified contactsEric, Chief Business Officer
Funding Insights
Based on industry dataTimeline to next round
Series B companies typically work for 15-20 months before raising new capital
Growth expectations
Series B companies are expected to scale rapidly and expand market reach
VC-backed spending patterns
VC-backed companies spend 89% more on sales and 100% more on marketing than bootstrapped peers
Tech investment trends
83% of B2B companies plan digital investments, with 79% prioritizing customer experience tech